TECHWIRE 30
(CIX: WRAL30)  1,132.61  up arrow+4.06  (0.36 %)  Updated: 08:10 PM EST, Nov 20 2014
(NQ: Apple)  116.31  up arrow+1.64  (1.43 %)  Updated: 08:10 PM EST, Nov 20 2014
(NY: QUINTILES)  57.75  up arrow+0.03  (0.05 %)  Updated: 06:40 PM EST, Nov 20 2014
(OP: BASF SE)  89.15  down arrow-0.7  (-0.78 %)  Updated: 05:20 PM EST, Nov 20 2014
(NQ: BioCryst)  10.35  up arrow+0.32  (3.19 %)  Updated: 08:10 PM EST, Nov 20 2014
(NQ: BioDelivery)  14.46  down arrow-0.25  (-1.7 %)  Updated: 08:10 PM EST, Nov 20 2014
(NQ: CEMP)  13.43  up arrow+0.21  (1.59 %)  Updated: 08:10 PM EST, Nov 20 2014
(NQ: Cisco Systems)  26.81  up arrow+0.22  (0.83 %)  Updated: 08:10 PM EST, Nov 20 2014
(NQ: Cree)  34.80  down arrow-0.34  (-0.97 %)  Updated: 08:10 PM EST, Nov 20 2014
(NQ: DARA)  0.75  down arrow-0.01  (-0.99 %)  Updated: 08:10 PM EST, Nov 20 2014
(NY: EMC CORPORATION)  29.86  down arrow-0.07  (-0.23 %)  Updated: 06:40 PM EST, Nov 20 2014
(NQ: Extreme Networks)  3.82  up arrow+0.06  (1.6 %)  Updated: 08:10 PM EST, Nov 20 2014
(NQ: FB)  73.60  up arrow+0.27  (0.37 %)  Updated: 08:10 PM EST, Nov 20 2014
(NY: GLAXOSMITHKLINE)  46.38  up arrow+0.13  (0.28 %)  Updated: 06:40 PM EST, Nov 20 2014
(NQ: GOOG)  534.83  down arrow-2.16  (-0.4 %)  Updated: 08:10 PM EST, Nov 20 2014
(NY: IBM)  160.64  down arrow-0.79  (-0.49 %)  Updated: 06:40 PM EST, Nov 20 2014
(NY: LH)  100.64  down arrow-0.31  (-0.31 %)  Updated: 06:40 PM EST, Nov 20 2014
(OP: Lenovo Group)  26.65  down arrow-0.27  (-1 %)  Updated: 05:20 PM EST, Nov 20 2014
(NY: MRK)  59.38  down arrow-0.26  (-0.44 %)  Updated: 06:40 PM EST, Nov 20 2014
(NQ: Microsoft Corp)  48.70  up arrow+0.48  (1 %)  Updated: 08:10 PM EST, Nov 20 2014
(NQ: NTAP)  42.20  up arrow+0.39  (0.93 %)  Updated: 08:10 PM EST, Nov 20 2014
(NY: NOVARTIS AG)  95.27  down arrow-0.46  (-0.48 %)  Updated: 06:40 PM EST, Nov 20 2014
(OP: Novozymes A/S)  46.42  down arrow-0.18  (-0.39 %)  Updated: 05:20 PM EST, Nov 20 2014
(NY: PFIZER)  30.44    (0 %)  Updated: 06:40 PM EST, Nov 20 2014
(NQ: Pozen)  8.93  up arrow+0.13  (1.48 %)  Updated: 08:10 PM EST, Nov 20 2014
(NY: RED HAT)  62.79  down arrow-0.15  (-0.24 %)  Updated: 06:40 PM EST, Nov 20 2014
(NQ: BBRY)  10.05  down arrow-0.14  (-1.37 %)  Updated: 08:10 PM EST, Nov 20 2014
(NQ: Salix)  100.43  down arrow-3.2  (-3.09 %)  Updated: 08:10 PM EST, Nov 20 2014
(NQ: SQI)  14.92  up arrow+0.11  (0.74 %)  Updated: 08:10 PM EST, Nov 20 2014

Posts tagged “Novartis”

Updated August 19, 2013

Premium Lock Chairman: Novartis, which has huge plant in Holly Springs, to review business units

International drug maker Novartis will start a strategic review of its units as early as next week and would consider a $10 billion purchase among options for bolstering the business, says new Chairman Joerg Reinhardt.

Novartis plant in Holly Springs Novartis plant in Holly Springs

Updated July 17, 2013

Premium Lock Novartis slashes ex-chairman's golden parachute to $6M from $78M

Novartis CEO Joe Jimenez, left, and former Chairman Daniel Vasella Novartis AG has cut former Chairman Daniel Vasella's payout to less than a tenth of the original $78 million, a sum that had helped galvanize support for a Swiss referendum on limiting executive pay.

Updated July 17, 2013

Premium Lock As blood pressure generic fails to materialize, Novartis ups full-year guidance

Novartis Europe's biggest drugmaker says it expects to lose $2.7 billion in sales to generic competition this year, 23 percent less than it previously forecast, as it continues to benefit from Ranbaxy Laboratories's failure to market a copycat version of the Diovan hypertension drug.

June 28, 2013

Premium Lock SAS, Quintiles slip on Europe 'Best Companies' list

Great Place To Work logo Several high-tech and life science firms based in North Carolina or who have a large presence here crack the "Best Multinationals" to work for list in Europe. But several of them also drop somewhat from the 2012 list.

February 22, 2013

Premium Lock Novartis chairman may keep working with firm as a consultant

Daniel Vasella Daniel Vasella, who is stepping down as chairman of international drug firm Novartis and decided not to accept a $78 million non-compete agreement, is now talking with the company about a consulting role.

February 19, 2013

Premium Lock No $78M golden parachute deal for Novartis chairman

Daniel Vasella Daniel Vasella, who is stepping down as chairman of international drug firm Novartis, cancels his $78 million agreement to not work for rival drug makers.

January 24, 2013

Premium Lock Will Novartis vaccine plant in Holly Springs be on auction block?

As drug maker Novartis goes through a change at the top with Chairman Daniel Vasella stepping down, investors celebrate the move and call for the company to spin off some assets such as its vaccine business.

Novartis' plant in Holly Springs Novartis' plant in Holly Springs

January 23, 2013

Premium Lock Novartis chairman stepping down; top Bayer exec to replace him

Novartis Daniel Vasella, the controversial Swiss executive who created drugmaker Novartis, unexpectedly said he will leave the board after 17 years, handing over to Bayer AG's top health-care executive.

Updated November 21, 2012

Premium Lock FDA approves Novartis vaccine made at Holly Springs plant

The U.S. Food and Drug Administration gives approval for a seasonal influenza vaccine produced at Novartis' new, huge production facility in Holly Springs.

Novartis plant in Holly Springs Novartis plant in Holly Springs

October 25, 2012

Premium Lock Nebraska drug plant problems plaguing Novartis

Novartis Novartis, which operates a large production plant as well as a research and development operation in Holly Springs, N.C., says shutdown Nebraska plant is hurting its consumer sales.

August 29, 2012

Premium Lock Novartis smoker's cough drug beats GSK's Advair in trial

Lung disease Patients taking Novartis's QVA149 were able to expel more air from their lungs in one second than those receiving Glaxo's best-selling Advair after 26 weeks of treatment, according to a summary of data from a trial.

August 29, 2012

Premium Lock Novartis experimental heart-failure drug shows promise

Heart research If successful, LCZ696 would be the first drug for patients with preserved ejection fraction, a condition in which the organ's ventricles still pump out more than 40 percent of the blood that comes in, but the atrium chamber fails to supply enough blood to the ventricle to meet the body's needs. The condition, which mainly affects women, accounts for about half of all heart failure patients.

August 7, 2012

Premium Lock Novartis funds $20M cancer facility at U. of Pennsylvania

Cancer research In exchange for the funding, the drug giant gains rights to the university's cancer technology that utilizes manipulated immune system stem cells.

June 19, 2012

Premium Lock Novartis, GSK win big biodefense center contracts

Pandemic Novartis along with Duke and NCSU will create a center for biodefense and to combat pandemic influenza in Holly Springs under a $60 million contract with the U.S. Department of Health and Human Services. GSK will work with Texas A&M on a $176 million deal.

Updated December 12, 2011

Premium Lock NCSU scientists to help spread new Novartis vaccine technology

NC biotech group hails formal dedication of the massive $1 billion Novartis plant in Holly Springs.

Novartis plant in Holly Springs Novartis plant in Holly Springs

December 8, 2011

Premium Lock Novartis drug plant in Wilson on FDA warning list

Novartis The U.S. Food and Drug Administration is taking Novartis CEO Joseph Jimenez to task with a warning letter that cites three of the company's manufacturing facilities for "significant violations" at the company's generics drug unit Sandoz.

November 4, 2011

Premium Lock Life science awards go to PPD, Novartis, Steve Burrill

Life science Scrips, an international life science media and related services firm based in the U.K., honors PPD with two awards, Novartis with three, and names Burrill its lifetime achievement winner.

Updated October 25, 2011

Premium Lock Novartis to cut 2,000 jobs, close 3 European plants

The drug giant, which operates a huge vaccine production and research facility in Holly Springs, says some jobs will be moved to the US as well as China and India.

Novartis plant in Holly Springs Novartis plant in Holly Springs

October 20, 2011

Premium Lock Novartis: 'Contagion' is fiction but threat is real

The movie "Contagion" is fiction, but ask Novartis executive Russell Thirsk and he'll tell you the threats it depicts are quite real.

September 6, 2011

Premium Lock Novartis fights patent rejection in Indian court

Novartis In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis AG for its lifesaving cancer treatment Gleevec.

Tags: Novartis
Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll